ABX196
Hepatitis B
PreclinicalActive
Key Facts
About Abivax
Abivax is a biopharmaceutical company focused on developing first-in-class therapies for inflammatory diseases and viral infections. Their lead candidate obefazimod represents a novel mechanism targeting RNA splicing to modulate immune responses. The company is publicly traded and has advanced multiple programs into clinical development, with a primary focus on inflammatory bowel disease and other immune-mediated disorders.
View full company profileTherapeutic Areas
Other Hepatitis B Drugs
| Drug | Company | Phase |
|---|---|---|
| GS-5245 | Gilead Sciences | Phase 2 |
| ARO-HBV | Arrowhead Pharmaceuticals | Phase 1 |